ライフサイエンスコーパス: or

1 mice, whereas deletion of Clec7a-the gene encoding dectin 1-or blockade of dectin 1 downstream signaling was protective.

2 Fifty-five percent of patients had grade 3 or 4 neurologic toxicities that completely resolved.

3 C-NVP) (647 of 1365 [47.4%]; ARR, 1.30; 95% CI, 1.20-1.41); or ZDV-3TC-LPV-R (75 of 167 [44.9%]; ARR, 1.21; 95% CI, 1.01-

4 orphotypes (efficacy 68.62% vs 76.72%; pinteraction=0.652); or between those with Lactobacillus spp morphotypes and those

5 h women (n = 660) with normal values (62%; 95% CI, 58%-66%) or after 12 cycles of attempt (70% [95% CI, 54%-80%] vs 76% [

6 nhibition of LDH activity by small hairpin ribonucleic acid or expression of phospho-deficient LDHA Y10F sensitized the c

7 ation of surface proteins revealed higher amounts of alpha4 or beta2 subunits in the LS or HS nAChR populations, respecti

8 omproportionate with a Mn(II) precursor to yield mu-oxo and/or mu-hydroxo Mn(III) dimers.

9 enile mouse, compared with time spent in nonsocial behavior or remaining immobile.

10 In those with significant comorbidities or those not undergoing surgery, competing causes of death ma

11 .0 years), 38 (15%) patients died and 106 (41%) either died or developed indication for mitral valve surgery.

12 randomized to the liberal (hemoglobin threshold, < 9 g/dL) or to the restrictive strategy (hemoglobin threshold, < 7 g/d

13 their firing according to simple spatial patterns (drifting or inverting gratings) without changes in irradiance.

14 ditional metabolic risk factor (hypertension, dyslipidemia, or diabetes) (aOR, 6.54 [95% CI, 1.87-22.88]).

15 s were categorized based on GDM/GH status (neither, either, or both).

16 inal charges, we develop CRY2high and CRY2low with elevated or suppressed oligomerization respectively, which we use to t

17 e an exclusive signature of cues unique to each environment or flower species.

18 he data of 2233 subjects who experienced either in-hospital or out-of-hospital cardiac arrest between January 2005 and Ma

19 e extracranial injuries (AIS >/= 3), death within 72 hours, or hospital stay <48 hours were excluded.

20 h RanBP9 and tau levels are simultaneously reduced by Hsp90 or Hsc70 inhibitors, whereas overexpression or knockdown of R

21 ease (American Joint Committee on Cancer [AJCC] stage 0, I, or II), and 48 (51.6%) were diagnosed with late-stage disease

22 .6%) were diagnosed with late-stage disease (AJCC stage III or IV).

23 Fatal infections or sepsis were significantly more common in the canakinumab g

24 a rationale for development of CXCR2 antagonists to inhibit or prevent metastatic spread of disease.

25 for the treatment of posterior tibial tendon insufficiency or chronic Achilles tendinopathy.

26 icating that no sources of target compounds were introduced or, that source introduction was not reflected in indoor air

27 hereas such phenotypes were reversed by its product lactate or antioxidant N-acetylcysteine, suggesting that Y10 phosphor

28 dings with increased prostate-specific antigen (PSA) level, or (c) had a prior history of prostate cancer with increasing

29 Many bacteria swim through liquids or crawl on surfaces by rotating long appendages called flage

30 yocytes from patients presenting in vivo with extremely low or high changes in cardiac repolarization in response to a ph

31 vealed higher amounts of alpha4 or beta2 subunits in the LS or HS nAChR populations, respectively.

32 y and optimized for simple screening assays with luciferase or fluorescent reporters.

33 The combined endpoint was cardiovascular death, MI, or stroke at 1 year.

34 educed by Hsp90 or Hsc70 inhibitors, whereas overexpression or knockdown of RanBP9 significantly diminishes the anti-tau

35 Interestingly, ASO-29 treatment at P1, P5 or P15 resulted in sufficient vestibular recovery to support

36 ge, follow-up time, timing of MRD assessment (postinduction or consolidation), MRD detection method, phenotype/genotype (

37 overed by culturing cells in the presence of a ROS quencher or in an anaerobic environment.

38 amics simulations of GLIC in the absence and presence of R- or S-ketamine.

39 h BE of >/= 1 cm did not differ significantly in age, race, or duration of follow-up.

40 Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM).

41 CJD by using the RT-QuIC assay on CSF samples, OM samples, or both.

42 inducing an endothelial cell (BmxCreER(T2)-driven)-specific or smooth muscle cell (SMC, SmmhcCreER(T2)- or TaglnCre-drive

43 arget of rapamycin inhibition by either nutrient starvation or use of an active site inhibitor reduces Skp2 levels and st

44 No patient had a manic switch or was hospitalized for a switch.

45 riven)-specific or smooth muscle cell (SMC, SmmhcCreER(T2)- or TaglnCre-driven)-specific deficiency of CXCR4 in an apolip

46 The transfer of the flexor hallucis longus tendon or flexor digitorum longus tendon is frequently used for the

47 .9+/-2.4 years, the primary end point of death, transplant, or admission for heart failure was reached in 88 patients.

48 iation between younger age and risk of definitive treatment or risk of biochemical recurrence after delayed RP.

49 nsporters and proteins crystallized in the presence of urea or urea derivatives.

50 ificantly different between women with detected G vaginalis or Bacteroides spp morphotypes and those without these morpho